ClinicalTrials.gg
CompletedNCT06229548Updated Apr 4, 2025

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

A Phase 1 interventional study of SYH2053 and Placebo in Hyperlipemia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
69th of 78
39 · median 155
Started
2024
with 10 others
Phase 1
19 of 94
4 open now
Registered
53rd of 94
by date

Among the 94 studies in Hyperlipidemias with a site in China, this one is the 69th largest by enrollment of the 78 interventional ones that give a count, is one of 11 that started in 2024, is one of 19 in phase 1, and was the 53rd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2053 when administered subcutaneously to subjects with normal and elevated LDL-C.

03

Conditions studied

  • Hyperlipemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must give before the trial, fully understand the content, procedures and possible adverse reactions, and voluntarily sign a written informed consent.
  2. Sex: male or female subjects.
  3. Age of 18 - 60 years (inclusive).
  4. : 18.6-28.5 kg/m\^2 (inclusive), with a minimum weight of 50 kg (inclusive) for male and 45 kg (inclusive) for female.
  5. During screening and baseline, LDL-C ≥100 mg/dL (2.6 mmol/L) and \< 190 mg/dL (4.9 mmol/L); TG ≤ 400 mg/dL (4.5 mmol/L); TC \< 278 mg/dL (7.2 mmol/L) in serum under fasting state;
  6. Subjects have no history of chronic or serious diseases or family history of early-onset coronary heart disease, including cardiovascular, liver, kidney, blood and lymphatic, endocrine, immune, psychiatric, neurological, and gastrointestinal systems, and are generally in good health.
  7. The subjects can communicate well with the investigators and complete the trial according to the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution or known history of allergy to the components of the study drug or similar drugs.
  2. Antibody drugs targeting PCSK9 have been used within 6 months prior to screening, oligonucleotides targeting PCSK9 have been used within 12 months prior to screening.
  3. There are currently medical disorders of clinical significance, including but not limited to, circulatory, hematological or hematopoietic diseases, respiratory, endocrine, urinary, digestive, neurological or psychiatric disorders, infections, tumors, severe trauma, or any other diseases that the investigator considers to be excluded or likely to interfere with the interpretation of the findings.
  4. Those who underwent major surgery within 6 months prior to initial administration, or who planned to undergo surgery during the study.
  5. abnormalities in vital signs, physical examination, and laboratory examination.
  6. The estimated (eGFR) during screening was \< 90 mL/min/1.73 m\^2 (calculated by simplified MDRD formula).
  7. During screening, any item of (ALT), aspartate aminotransferase (AST), total (TBIL), γ-glutamyltransferase (GGT), alkaline phosphatase (ALP) > 1.5× (retest once within 1 week allowed).
  8. During screening or baseline, subjects with prolonged /QTc interval (QTcF > 450 ms in male, > 470 ms in female).
  9. Subjects with non-negative test for any of , antibodies, syphilis antibodies, and antibodies.
  10. Blood loss or blood donation of more than 200 mL within 3 months prior to administration (except for female menstrual period), and/or donation within 2 weeks prior to administration.
  11. Use of any drug, supplement, vitamin or dietary supplement known to affect lipid metabolism within 28 days prior to administration; use of any drug for therapeutic purposes (except topical drugs with local effects) within 14 days prior to administration or within the 7 half-lives of the drug (whichever is longer).
  12. A history of drug abuse, and/or drug use within 3 months prior to screening, and/or habitual use of any psychotropic drug, including Chinese herbs.
  13. Positive urine drug screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    SYH2053 SAD experimental group

    Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH2053 on Day 1.

    Drug: SYH2053

  • Placebo comparator
    Placebo SAD group

    Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.

    Drug: Placebo

Interventions

  • subcutaneous injection

  • DrugPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. The Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0

    The investigator will make an assessment of intensity for each AE and SAE reported during the study according to CTCAE V5.0

    Time frame: Pre-dose and multiple timepoints no less than 57 days

Secondary outcomes

  1. The serum LDL-C level after dosing SYH2053

    measure the LDL-C level in blood by lab examination and evaluate the effect of SYH2053 on LDL-C Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  2. The serum PCSK9 level after dosing SYH2053

    measure the PCSK9 level in blood by lab examination and evaluate the effect of SYH2053 on PCSK9 Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  3. PK parameters (Cmax)

    maximum peak observed plasma SYH2053 concentration in treated subjects

    Time frame: Pre-dose and multiple timepoints up to 4 days

  4. PK parameters (Tmax)

    time to reach maximum peak plasma SYH2053 concentration in treated subjects

    Time frame: Pre-dose and multiple timepoints up to 4 days

  5. PK parameters (AUC)

    area under the plasma concentration-time curve in SYH2053 treated subjects

    Time frame: Pre-dose and multiple timepoints up to 4 days

  6. PK parameters (T1/2)

    the elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve in SYH2053 treated subjects

    Time frame: Pre-dose and multiple timepoints up to 4 days

  7. Immunogenicity of SYH2053

    Rate of formation of anti-drug antibodies to SYH2053

    Time frame: Pre-dose and multiple timepoints up to 57 days

  8. The serum TC level after dosing SYH2053

    measure the TC level in blood by lab examination and evaluate the effect of SYH2053 on TC Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  9. The serum TG level after dosing SYH2053

    measure the TG level in blood by lab examination and evaluate the effect of SYH2053 on TG Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  10. The serum HDL-C level after dosing SYH2053

    measure the HDL-C level in blood by lab examination and evaluate the effect of SYH2053 on HDL-C Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  11. The serum Lp(a) level after dosing SYH2053

    measure the Lp(a) level in blood by lab examination and evaluate the effect of SYH2053 on Lp(a) Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  12. The serum VLDL-C level after dosing SYH2053

    measure the VLDL-C level in blood by lab examination and evaluate the effect of SYH2053 on VLDL-C Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  13. The serum non-HDL-C level after dosing SYH2053

    measure the non-HDL-C level in blood by lab examination and evaluate the effect of SYH2053 on non-HDL-C Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  14. The serum ApoA1 level after dosing SYH2053

    measure the ApoA1 level in blood by lab examination and evaluate the effect of SYH2053 on ApoA1 Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  15. The serum ApoB level after dosing SYH2053

    measure the ApoB level in blood by lab examination and evaluate the effect of SYH2053 on ApoB Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

  16. The serum hsCRP level after dosing SYH2053

    measure the hsCRP level in blood by lab examination and evaluate the effect of SYH2053 on hsCRP Level

    Time frame: Pre-dose and multiple timepoints no less than 57 days

07

Study locations

1 site
  • 10 Chedaogou Rd.,Haidian District, Beijing, China
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2024, 11 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 11 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 29, 2024
StartActual
Jan 8, 2024
Primary completionActual
Dec 23, 2024
CompletionActual
Mar 25, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06229548
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Jan 8, 2024
Primary completion
Dec 23, 2024
Completion
Mar 25, 2025
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYH2053

Start the discussion